About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Is Duloxetine More or Less Effective Than Fluoxetine?

by Bidita Debnath on May 24, 2014 at 11:46 PM
Font : A-A+

 Is Duloxetine More or Less Effective Than Fluoxetine?

Studies of the anti-depressive drug duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), compared its safety and effectiveness to either fluoxetine or placebo in children and adolescents with major depressive disorder (MDD).

The results of these first controlled trials of duloxetine in pediatric patients with MDD are published in Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The articles are available free on the Journal of Child and Adolescent Psychopharmacology.

Advertisement

Graham Emslie, MD and coauthors evaluated the efficacy and safety of a fixed dose of duloxetine—either 60 mg or 30 mg once a day—versus 20 mg daily of fluoxetine or placebo in children ages 7-11 years and adolescents ages 12-17 years. In the article "A Double-Blind Efficacy and Safety Study of Duloxetine Fixed Doses in Children and Adolescents with Major Depressive Disorder" they compare the treatments based on worsening of suicidal ideation, emergence of suicidal behavior, and adverse effects including abnormal findings on an electrocardiogram and laboratory tests.

Sarah Atkinson, MD and colleagues compared a flexible dosing regimen of duloxetine (60-120 mg daily) to fluoxetine (20-40 mg daily) or placebo and reported measures from a depression rating scale and a suicide severity rating scale, as well as treatment-related adverse events, in the article "A Double-Blind Efficacy and Safety Study of Duloxetine Flexible Dosing in Children and Adolescents with Major Depressive Disorder".
Advertisement

Neither study found a significant difference in response between the two drugs and placebo. The authors suggest that this may be due to the complexity of these novel studies and offer observations that may direct the design of future investigations.

"Drs. Emslie and Atkinson and their colleagues took a fascinating approach towards testing the efficacy of a novel SNRI in the pediatric population," said Harold S. Koplewicz, MD, Editor-in-Chief of Journal of Child and Adolescent Psychopharmacology, and President, Child Mind Institute, New York, NY. "Researchers are of course excited by positive results, but in this case the curious lack of response tells us volumes about how to better design complex studies—studies that may soon give us uncommon insight into our pharmacologic interventions."

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Organ Donation Week 2022 - 'Take the Pledge to Save Lives'
Test your Knowledge on Heart Transplantation
Test Your Knowledge on Lung Transplantation
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Amoebic Dysentery 

Most Popular on Medindia

Daily Calorie Requirements Diaphragmatic Hernia Calculate Ideal Weight for Infants The Essence of Yoga Color Blindness Calculator Sinopril (2mg) (Lacidipine) Sanatogen Indian Medical Journals Turmeric Powder - Health Benefits, Uses & Side Effects Drug Side Effects Calculator
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use